

Harnessing AI and Quantum Computing: Revolutionizing Drug Discovery and Approval Processes Using Collagen as an Example

Bharat Rawal, David Melvin Braga

Submitted to: JMIR Bioinformatics and Biotechnology
on: December 09, 2024

Disclaimer: © The authors. All rights reserved. This is a privileged document currently under peer-review/community review. Authors have provided JMIR Publications with an exclusive license to publish this preprint on its website for review purposes only. While the final peer-reviewed paper may be licensed under a CC BY license on publication, at this stage authors and publisher expressly prohibit redistribution of this draft paper other than for review purposes.

Table of Contents

Original Manuscript.....	5
Supplementary Files.....	19
.....	19
Figures	20
Figure 1.....	21
Figure 2.....	22
Figure 3.....	23
Related publication(s) - for reviewers eyes onlies	24
Related publication(s) - for reviewers eyes only 0.....	25
TOC/Feature image for homepages	26
TOC/Feature image for homepage 0.....	27

Harnessing AI and Quantum Computing: Revolutionizing Drug Discovery and Approval Processes Using Collagen as an Example

Bharat Rawal¹ Prof Dr, PhD; David Melvin Braga² PhD

¹ Grambling State University Grambling US

² Capitol Technology University Laurel US

Corresponding Author:

Bharat Rawal Prof Dr, PhD

Grambling State University
403 Main Street, Grambling, Louisiana 71245
Grambling
US

Abstract

Background: Computational data generated from Digital Computers, Artificial Intelligence, and Quantum Computing will change the course of new drug discovery and approval by accelerating and optimizing the process of identifying potential drug candidates through creating computational data, predicting the efficacy of pharmaceuticals, and assessing their safety.

Objective: This study aims to identify if computational data from Digital Computers, Artificial Intelligence, and Quantum Computing in computer-aided drug development can reduce the number of laboratory and animal experiments by providing safe and effective combinations while minimizing the costs and time in drug development. This will suggest computational models based on Digital Computers, Artificial Intelligence, and Quantum Computing.

Methods: Overall, 83 academic publications were reviewed, pharmaceutical manufacturers were interviewed, and AI was utilized to run computational data. The research evidence mainly focused on the ability to create computational virtual data to be compared to actual laboratory data and the use of this data to discover or approve newly discovered drugs.

Results: Digital computers, artificial intelligence, and quantum computing offer unique capabilities to tackle complex problems in drug discovery, which is a critical challenge in pharmaceutical research. Regulatory agents will need to adapt to these new technologies. Regulatory processes may become more streamlined, utilizing adaptive clinical trials, accelerating pathways, and better integrating digital data to reduce the time and cost of bringing new drugs to market.

Conclusions: Computational data methods could be used to reduce the cost and time involved in experimental drug discovery, allowing researchers to simulate biological interactions and screen large compound libraries more efficiently. Creating virtual data for drug discovery involves several stages, each utilizing specific methods such as simulations, synthetic data generation, data augmentation, and tools to generate, collect, and affect human interaction to identify and develop new drugs. Clinical Trial: N/A

(JMIR Preprints 09/12/2024:69800)

DOI: <https://doi.org/10.2196/preprints.69800>

Preprint Settings

1) Would you like to publish your submitted manuscript as preprint?

Please make my preprint PDF available to anyone at any time (recommended).

Please make my preprint PDF available only to logged-in users; I understand that my title and abstract will remain visible to all users.

Only make the preprint title and abstract visible.

✓ **No, I do not wish to publish my submitted manuscript as a preprint.**

2) If accepted for publication in a JMIR journal, would you like the PDF to be visible to the public?

✓ **Yes, please make my accepted manuscript PDF available to anyone at any time (Recommended).**

Yes, but please make my accepted manuscript PDF available only to logged-in users; I understand that the title and abstract will remain visible to all users.

Yes, but only make the title and abstract visible (see Important note, above). I understand that if I later pay to participate in <http://www.jmir.org>

No. Please do not make my accepted manuscript PDF available to anyone. I understand that if I later pay to participate in <https://www.jmir.org>



Original Manuscript

Harnessing AI and Quantum Computing: Revolutionizing Drug Discovery and Approval Processes

David Melvin Braga¹ and Bharat Rawal²

¹Capitol Technology University, 11301 Springfield Road Laurel, MD 20708

²Grambling State University, Grambling, LA 71270

¹dbraga@captech.edu, ²rawalb@gram.edu

Abstract

Computational data generated from artificial intelligence (AI) and quantum computing will change the course of new drug discovery and approval by accelerating and optimizing the process of identifying potential drug candidates by creating computational data, predicting the efficacy of pharmaceuticals, and assessing their safety. This paper aims to highlight how the computational data from AI and Quantum Computing can reduce the number of laboratory and animal experiments in determining toxicity by providing safe and effective combinations while minimizing the costs and time in drug development. The paper discusses computational models based on AI and Quantum Computing. Academic publications were reviewed, AI and Quantum Computing were utilized to run computational data, and laboratory data was gathered. The research evidence mainly focused on the ability to create computational virtual data of the toxicity of one drug to be compared to actual laboratory data. The secondary data show that the computed assessment of the toxicity of a drug is the same as the toxicity data performed in a laboratory at a considerable fraction of the cost.

1. Introduction

The discovery and approval process are characterized by significant financial investment with costs ranging from one to \$3 billion and a typical timeline of 10 years alongside a 10% success rate. These highlights are critical for innovative approaches to enhance efficiency in the drug development pipeline, computational methods have the potential to influence the FDA approval process by providing reliable data that could lead to faster review cycles and more efficient safety evaluation [1].

Despite the advantages of computational methods, there remains a research gap in their acceptance by regulatory agencies compared to traditional laboratory and animal studies ISO 10993-5 serves as the standard for assessing the cytotoxicity of materials the necessity for a rebut foundation to validate computational models within a regulatory framework This study demonstrates that computational data regarding the toxicity of the filler drug collagen generated by allies with laboratory results the supporting the integration of computational methods in drug development[2].

Investments in drug research and development are often lengthy and complex. With AI and quantum computing, we present new opportunities for accelerating the identification of potential drug candidates while enhancing safety and efficacy predictions [3]. Digital Health Technologies [DHT] in drug development can be used to measure the drugs by using data derived from a DHT in a drug need to determine what data would be required to support and support their findings with analysis that the FDA can accept [4] collecting data from data sources such as gene side effect profile, and the time to developing new drugs [5].

This study aims to illustrate how computational methods can significantly reduce costs and timelines traditionally associated with drug development ultimately improving patient safety through better informed regulatory decisions. Some of the use cases with AI and quantum for drug discovery processes are listed below.

1.1 AI's Role in the Discovery of New Drugs

Investments in new drug development are a long and complex process of drug research and development (R&D); however, with the advancement of AI, technology has emerged as a leading tool in analyzing potential new drugs. AI can be used to learn the possible patterns of biomedical data, bringing new potential to the pharmaceutical drug manufacturing industry [6].

AI can be used in the complete life cycle of a pharmaceutical drug, including target discovery, drug discovery, preclinical research, drug safety, drug efficacy, clinical trials, drug manufacturing, and approval to market [6]. AI can be used in each drug discovery phase, giving research access to new materials. New data is constantly being added to the drug repositories. Combining ligand and structure-based virtual screening methods allows researchers to screen large chemical databases quickly to identify potential drug candidates [7]. Although it can help accelerate new drug discoveries, accuracy is paramount if the data is to be used by researchers and regulators alike. AI, machine learning, Virtual drug compound libraries, and Quantum Computing technologies are crucial to drug discovery and development.

1.2 Use of AI for Target Identification of New

Drugs

AI systems can analyze diverse data types, such as genetic, proteomic, and clinical data, to identify potential therapeutic targets. By uncovering disease-associated targets and molecular pathways, AI assists in designing medications that can modulate biological processes [8]. By analyzing complex datasets, AI can find potential new and novel drug candidates, delivering a paradigm shift from traditional laboratory trial-and-error methods [8]. The value of AI is that it significantly delivers potential new drugs at a reduced timeframe and cost perspective, and predicts drug-target interactions, optimizes drug design, predicts clinical outcomes, accelerates drug screening, repurposes existing drugs while reducing costs and time. This capability is sufficient because it is possible to find cures for the most urgent medical needs plaguing mankind. Daily, vast amounts of new drug compound data are added to virtual databases. Virtual screening is a computational technique used in drug discovery to search for potential drug candidates.

1.3 Virtual Screening of New Drugs

AI enables the efficient screening of vast chemical libraries to identify drug candidates with a high likelihood of binding to a specific target. New simulation methods, such as Quantum Computing and AI, can significantly compress the timeline and cost of discovering new drugs [9]. There are already virtual libraries that hold over eleven billion compounds; however, new approaches to compound screening are needed to keep pace with the rapid growth of virtual libraries [10]. The modular nature of virtual libraries supports their further rapid growth beyond ten billion drug-like compounds [10]. By simulating chemical interactions and predicting binding affinities, AI helps researchers prioritize and select compounds for experimental testing, saving time and resources. Exploring new compounds is unlimited and unmapped, and advanced technology such as AI will help facilitate exponential growth in virtual libraries. Utilizing large databases of chemical compounds that might have potential drug uses helps researchers simulate the interaction between drug candidates and target proteins to predict binding affinities and possible toxicity. This approach accelerates the drug discovery process, reduces costs, identifies potential toxicity conflicts, and enhances the identification of promising drug candidates.

1.4 Molecular Docking for New Drugs

For virtual screening to be cost-effective and timely, compound libraries that include known drug-like molecules must be built. Protein molecules are evaluated using molecular docking to identify those that can bind to a target protein active binding site [11]. Molecular Docking can efficiently prepare highly entangled states that perform essential quantum chemistry and machine learning tasks beyond digital

computers' capacity [12] [13]. Molecular Docking predictive capabilities can be utilized to study how a drug will bind to forecast pharmacological and potential side effects. Most of the identification of molecules that exhibit potential against a disease focuses on potential proteins of low molecular weight, constituting seventy-eight percent of the drug market [14]. Molecular Docking will eventually replace traditional trial-and-error methods with the potential of cost and timesaving instead of conducting longitudinal studies that may last for years without a guaranteed outcome. If a protein is identified, the computation is not wasted; it is added to the virtual library. Digital computer searches for new proteins generally produce low hit rates and require the synthesis of many compounds, adding to the time and expense of drug discovery.

1.5 Molecular Modeling

Traditional computing methods struggled to simulate quantum effects in huge molecules accurately. Computational methods for Quantum computing allow more detailed simulations of molecules' behavior and their interaction with potential drug compounds [15]. This helps researchers understand how molecules fold, bond, or interact, leading to the more rapid identification of promising drug candidates.

Regulatory bodies like the US Food and Drug Administration [FDA] [16] rely on empirical data from laboratory experiments and clinical trials to evaluate the safety and efficacy of new drugs, medical devices, and food products. This empirical evidence is critical for ensuring the safety of these products for public use. Computational data, experimentation, comparison Computational data, experimentation, and quantum calculations can increasingly inform and improve drug discovery efforts in a scoring system for the calculated probability of success given the specific conditions. n, and quantum calculations require a complex series of simulations combining quantum chemistry and molecular dynamics to predict how a new drug might interact with toxins or undergo structural transformations that could influence toxicity.

1.6 ISO 10993 Computational Data for Pre-Biocompatibility

ISO 10993-5 is the corresponding test for determining the cytotoxicity of materials. Preclinical biocompatibility is the first step in the drug discovery process. It refers to the testing and evaluating the medical devices, materials, or pharmaceuticals to ensure they are compatible with biological systems before they are used in humans [17]. These tests are critical for determining whether a product causes any adverse effects, such as toxicity, allergic reactions, or tissue damage, when it comes into contact with living tissues. The pharmaceutical company must submit the information before clinical trials can start for a new drug. In pre-clinical biocompatibility, the materials used in a drug are tested in vitro [in the lab] and in vivo [in animals] to assess factors like:

Contribution of the paper

- 1) **Accelerated Drug Discovery:** The paper highlights how AI and quantum computing can significantly expedite the identification of potential drug candidates by creating computational models that predict drug efficacy and safety, thus reducing the time required for drug development.
- 2) **Reduction of Laboratory Testing:** It discusses the potential of computational data to minimize the reliance on laboratory and animal experiments for toxicity assessments, thereby lowering costs and streamlining the drug approval process.
- 3) **Integration of AI in Target Identification:** The authors emphasize the role of AI in analyzing diverse datasets to identify therapeutic targets, thereby enhancing the efficiency of drug design by revealing novel drug candidates associated with specific diseases.
- 4) **Use of Virtual Screening:** The paper details how AI facilitates the efficient screening of vast chemical libraries, allowing researchers to prioritize compounds likely to bind effectively to target proteins, thus optimizing the drug discovery pipeline.
- 5) **Molecular Docking and Modeling:** The authors present molecular docking techniques as essential tools for evaluating potential drug interactions with target proteins, highlighting their ability to replace traditional trial-and-error methods with more systematic approaches.
- 6) **Regulatory Implications:** Finally, the paper discusses the need for regulatory agencies to adapt to the integration of AI and quantum computing in drug development, suggesting that computational models could reshape the FDA's drug approval processes, leading to more efficient regulatory frameworks.

The remaining sections of the study are organized in the

form of shadows: The relevant works are summarized in Section 2, the suggested method is briefly explained in Section 3, result is presented in Section 4, Challenges with uses of AI are presented in Section 5, and discussion is provided in Section 6, and limitations are listed in Section 7. Section 8, future work, and conclusion are provided in Section 9.

2. Related works

The potential of using a detailed structural model of proteins will accelerate the drug discovery process by providing researchers with the atomic configuration that drives the design or selection of compounds at a molecular level. The simulation of dynamic and complex systems, which is significant in comprehending the nature of a drug, is considered one of the most essential and promising applications of quantum computers [18]. Fundamental building blocks of atoms, molecules, and proteins can add to human understanding, enrich simulation with computational modeling, and help explore material [19]. Vast databases of protein structures can now be predicted using bioinformatics models [20]. Using AI, Digital Computers, Quantum Computing, and Virtual Libraries together will deliver a paradigm shift in discovering and approving new drugs. From this paradigm, the trend will be from traditional laboratory trial-and-error or hypothesis-driven methods to computational data-driven models. This paradigm will expand the potential for predicting and understanding potential new drugs at a molecular level better to understand drug interactions, toxicity, and efficacy.

Hassan, A., & Ibrahim, A. explore the anticipated evolution of quantum computing in the pharmaceutical industry and drug research and development. They discuss the transformative potential of quantum technologies in enhancing drug discovery processes and the need for industry adaptation to these advancements [14]. Srivastava, R. has discussed the emerging role of quantum computing in drug discovery, highlighting its potential to solve complex biological problems more efficiently than classical computing. The author emphasizes the need for further research to fully harness quantum technologies in pharmaceutical applications, particularly in molecular simulations and drug design [27]. Cova, T., et al. explores how AI and quantum computing are poised to disrupt the pharmaceutical industry. It outlines the synergistic benefits of combining these technologies to enhance drug design processes, improve predictive models, and accelerate the overall drug development timeline [28]. Rayhan, A., & Rayhan, S., have examined the intersection of quantum computing and AI, proposing that their integration represents a significant advancement in computational intelligence. They discuss how these technologies can enhance data analysis and modeling in drug discovery, leading to more effective therapeutic solutions [29]. Pyrkov, A., et al., reviews the near-term applications of quantum computing in generative chemistry and drug discovery.

The authors highlight specific cases where quantum algorithms can optimize molecular design and predict drug interactions, showcasing the transformative potential of quantum technologies in pharmaceutical research [30].

Kumar, G., et al., provides an overview of recent advancements in quantum computing for drug discovery and development. The authors discuss various quantum algorithms and their applications in enhancing the efficiency of drug design processes, emphasizing the importance of interdisciplinary collaboration in this field [31]. Cao, Y., et al., explore the potential of quantum computing for drug discovery, focusing on its ability to perform complex calculations that are infeasible for classical computers. They discuss the implications of quantum technologies for molecular modeling and the future of pharmaceutical research [32]. Mishra, R., et al., discuss the promise of quantum computing in drug discovery, detailing how quantum algorithms can improve drug delivery systems and enhance the precision of pharmaceutical development. The authors advocate for the continued exploration of quantum technologies to address current challenges in drug design [33].

Sharma, P. highlights the role of quantum computing in drug design, emphasizing its potential to enhance precision and efficiency in pharmaceutical development. The author discusses various quantum techniques that can be applied to optimize drug candidates and streamline the development process [34]. Popa, R., & Dumitrescu, E., investigated the promises and potential of quantum machine learning in drug discovery. They discussed how these advanced computational techniques can facilitate the identification of new drug candidates and improve the overall efficiency of the drug development pipeline [25]. Chow, J. C., reviews the applications of quantum computing in medicine, particularly in drug discovery. The author discusses how quantum technologies can enhance molecular simulations and improve the accuracy of drug design, ultimately leading to better therapeutic outcomes [35].

3. Methods

3.1 Using AI to Determine the Drug Toxicity of Collagen

The derma filler drug Collagen was one of the first cosmetic fillers used to reduce wrinkles, add volume, and improve skin texture. These fillers are injected beneath the skin to smooth out lines and restore lost facial volume, helping achieve a youthful appearance. All newer materials, like hyaluronic acid HIV fillers, have replaced mainly collagen and cosmetic

procedures. Collagen fillers still offer benefits in specific cases. In this example, it was demonstrated that AI computations can effectively match actual laboratory results.

The chemical structure must be known to compute the toxicity of collagen Fig. 1 and 2]. Understanding the toxicity of drugs is crucial to ensure their safety and effectiveness. Toxicity testing is a fundamental step in drug development and regulatory approval to minimize harm to patients and maximize therapeutic benefits. To determine the drug's toxicity, the chemical structure of drugs plays a pivotal role in discovering and designing new drugs. By understanding the molecular makeup, researchers can predict how long a drug might interact or how a drug might interact with biological targets, leading to effective treatment options. By leveraging chemical structures in these ways, drug discovery becomes more efficient, targeted, and capable of producing effective treatments faster. The ability to predict a compound's behavior based on structure helps minimize experimental costs and speed up the path from discovery to clinical application.

Collagen is a large and complex protein. SMILES [simplified molecular input line entry system] is a way to represent the structure of a molecule as a line of text, making it easier for computers to interpret. In SMILES, each molecule is detected by a string of letters, numbers, and symbols that encode its atoms, bonds, and conductivity. SMILES is typically used to represent small molecules, while collagen is a polymer composed of long chains of amino acids in a specific sequence. Representing collagen and smiles requires the representation of each amino acid in the chain, making it formats to study or represent collagen structurally.

Smiles are essential in chemical and pharmaceutical informatics, facilitating digital storage, analysis, and manipulation of drug molecules in various research and development applications. For the evaluation of Collagen's toxicity, the following:

Researchers typically use protein structure Data Bank] files, which describe the three-dimensional coordinates of atoms in the protein.

```
(3H)C(CC(C@@H)(C(=O)NCC(=O)N(C@@H)
(CC1C=NC=N1)C(=O)N(C@@H)
(CCCN=C(N)N)C(=O)NCC(=O)N(C@@H)
(CC2=CC=CC=C2)C(=O)N(C@@H)
(CO)C(=O)NCC(=O)OC(=O)(C@H)
(CC(C)C)NC(=O)CN(C(=O)C@H)
(CCCC)NC(=O)CNC(=O)(C@@H)3C(C@H)
(CN3)O)C([3H])N
```

The Molecular Formula of Collagen:

$C_{57}H_{91}N_{19}O_{16}$ [21]



Fig 1. Crystal structure of Type IV collagen from Bovine [22]. Knowing the crystal structure of drugs is critically important in determining drug toxicity because the molecular arrangement and interactions in the solid state can significantly influence the drug's behavior, stability, and interactions within biological systems.

1.1 2D Structure




Fig 2. Chemical Structure Depiction of Collagen [23] molecular arrangement and stability. The crystal structure revealed the three-dimensional arrangement of molecules in the drug. The crystal form can affect the drug's chemical stability and shelf life. A less stable form may degrade into toxic byproducts. The crystal structure can influence how enzymes metabolize a drug. The orientation of function groups in the crystal lattice can affect how enzymes process the drug.

3.2 Using Quantum Computations to Determine the Drug Toxicity of Collagen

Traditional computing methods struggled to simulate quantum effects in molecules, especially huge ones accurately. Quantum computing allows more detailed simulations of molecules' behavior and their interaction with potential drug compounds. This helps researchers understand how molecules fold, bond, or interact, leading to the more rapid identification of promising drug candidates.

The following is a Python code used for setting up and running the VQE simulation.

1. Define a glycine-proline-hydroxyproline fragment as a molecule.

For simplicity, we use approximate coordinates for the atoms.

```
molecule = Molecule (
    geometry= ([
        ("N", (0.0, 0.0, 0.0)),
        ("C", (1.0, 0.0, 0.0)),
        ("C", (2.0, 1.0, 0.0)),
        ("O", (2.0, 2.0, 0.0)),
        ("H", (-0.5, -0.5, 0.5)),
```

Additional atoms for the fragment would follow similarly

- ```
), charge=0, multiplicity=1)
```
2. Set up the quantum chemistry driver using PySCF for initial DFT calculation.

```
driver=PySCFDriver (molecule=molecule,
 basis="sto3g") # Use small basis set for simplicity
```

3. Set up the electronic structure problem
- ```
es_problem = ElectronicStructureProblem(driver)
```

4. Map the problem to qubits using a qubit converter and Jordan-Wigner transformation

```
Qubit_converter = QubitConverter[mapper=JordanWignerMapper()]
```

The optional process is to apply a core orbital freezing transformation to reduce the number of qubits

```
transformer = FreezeCoreTransformer()
es_problem = transformer.transform(es_problem)
```

5. Set up the ansatz and optimizer for VQE
- # EfficientSU2 is a standard hardware-efficient ansatz with two-qubit entanglement

```
ansatz = EfficientSU2(qubit_converter.num_qubits,
    entanglement="full", reps=2)
```

```
optimizer = COBYLA (maxiter=500)
```

6. Define the quantum instance [statevector simulator] to simulate the VQE

```
quantum_instance = QuantumInstance[backend=Aer.get_backend("statevector_simulator")]
```

7. Set up the VQE solver with the ansatz, optimizer,

and quantum instance.

```
vqe_solver = VQE [ansatz=ansatz,
    optimizer=optimizer,
    quantum_instance=quantum_instance]
```

```
calc = GroundStateEigensolver[qubit_converter,
    vqe_solver]
```

8. Compute the ground-state energy of the collagen fragment

```
result = calc.solve(es_problem)
```

Display the computed ground-state energy

```
print["Computed ground state energy for glycine-proline-hydroxyproline fragment:", result.total_energy].
```

Explanation of Each Step:

1. Molecule Definition:

The molecular structure of glycine, proline, and hydroxyproline are simplified here using approximate coordinates. The process could use accurate coordinates from databases or experiments in a more detailed setup.

2. Driver Setup [PySCF]:

The PySCF driver performs a classical DFT calculation on the molecule, generating an initial electronic structure. This structure is converted into a qubit operator by Qiskit Nature for quantum processing.

3. Qubit Mapping and Core Freezing:

The Qubit Converter converts molecular orbitals into qubits using the Jordan-Wigner transformation. Freezing core orbitals reduces qubit requirements, making the problem more manageable on current quantum hardware.

4. Ansatz and Optimizer Selection:

An EfficientSU2 ansatz was used with a full entanglement pattern to capture the electronic correlations in the fragment. This ansatz is hardware-efficient, making it suitable for quantum simulations.

5. Quantum Instance:

A state vector simulator is used to simulate quantum computation. This provides precise energy results without the noise found in current quantum hardware.

6. Run VQE and Calculate Ground State Energy:

The VQE algorithm iteratively optimizes the circuit parameters to minimize the system's energy, approximating the ground-state energy of the collagen fragment.

The Ground-State Energy output represents the ground-state energy for the glycine-proline-hydroxyproline fragment. This energy provides insights into the stability of the fragment and, by extension, collagen's stability.

Potential Extensions and Next Steps:

1. Excited States: Using methods like Quantum Subspace Expansion (QSE) or Variational Quantum Deflation (VQD), the process could extend this setup to compute excited states, enabling HOMO-LUMO gap estimation.

2. Binding Energy Calculations: By setting up another VQE calculation for a binding partner (e.g., a drug or mineral) and calculating the energy difference, you can estimate binding interactions relevant for drug design and collagen stability.
3. Error Mitigation Techniques: When moving from simulation to actual quantum hardware, employ error mitigation methods like Zero-Noise Extrapolation (ZNE) and Measurement Error Mitigation (MEM) to improve accuracy.

This process provides a foundation for exploring collagen's electronic structure using quantum computing. As quantum hardware advances, these methods will become increasingly feasible for larger fragments and more comprehensive models of collagen.

While the methods simplify the complexity inherent in modeling collagen at the quantum level, they illustrate the foundational principles used in computational chemistry to study large biological molecules. Actual implementations for full-length collagen or even longer peptides would require more sophisticated models and computational strategies, typically relying on approximations and empirical data to achieve feasible and accurate results.

3.3 Using Laboratory Methods to Determine the Drug Toxicity of Collagen

An increasing number of soft tissue filler substances are introduced to the beauty market outside the US, which often needs more experimental and clinical data to support their claim. Numerous materials have been evaluated for their utility in correcting facial folds and other skin defects. Bovine collagen suspensions, available commercially since 1981, are the most widely used injectable biological material for soft tissue correction. The transient results of collagen suspensions are well known to physicians and patients and require repeated material injections to sustain the desired effect. There remains a clinical need for material that can be used to correct facial wrinkles and augment skin defects, and which is not re-absorbed at the injection site as are all biological materials or does not have inherent limitations of synthetic materials currently used such as granuloma formation, chronic inflammation or margin visibility.

The collagen used in Derma Filler is atelocollagen, which consists of three separate helix-shaped α -chains

(polypeptide chains), which wrap around each other and form a three-stranded helix. Amino acid analysis shows that this is collagen type 1. Each polypeptide chain contains about 1,000 cross-linked amino acids. The collagen molecule consists of two identical polypeptides (α -1(1)) and a third polypeptide chain that has a different amino acid sequence (α -2(1)). The individual polypeptide chains can be separated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE).

Derma filler is indicated for correcting contour deficiencies of soft tissue. Wrinkles develop because the thickness of the skin's dermal layer significantly diminishes during aging.

Derma Filler in this study was composed of absolutely round and smooth PMMA microspheres, 30 to 42 microns in size, suspended in a water-based carrier gel containing 3.5% bovine collagen, 96.5% buffered, isotonic water for injection, and 0.3% lidocaine [23].

For the laboratory PMMA, microspheres are suspended in a solution of partly denatured 3.5% bovine collagen. Following the injection of Derma Filler, the collagen vehicle is absorbed by the body within 1-3 months, during which the non-degradable PMMA microspheres stimulate the body to encapsulate each sphere with the patient's collagen. This results in a long-lasting correction of wrinkles and other soft tissue defects [23].

The collagen used in Derma Filler is a solution of 3.5% bovine collagen, 96.5% buffered, isotonic water for injection, and 0.3% lidocaine. Bovine collagen is converted to atelocollagen by treatment with pepsin to remove the peptide ends, thus reducing its antigenic potential [22].

3.4 Using AI to Determine the Drug Toxicity of Collagen

AI algorithms were used to predict toxicity based on compounds' chemical and biological properties. AI uses neural networks to analyze molecular graphs or sequences to detect toxicity-related patterns.




Fig. 3 The virtual calculation of the blood-brain barrier shown in Figure 12 [23], which effectively protects brain tissue from circulating pathogens and other potentially toxic substances, shows the toxicity of Collagen to be low. Collagen itself is shown to be safe and non-toxic.

PARAMETER	SPECIFICATION	METHOD
Collagen [calculated from hydroxyproline]	3.0% - 4.0%	Spectrophotometric
Hydroxyproline	0.41% - 0.55%	Spectrophotometric
Lidocaine HCl	0.27% - 0.33%	HPLC
Heavy Metals	< 20 ppm	DAB 10
PH	6.8 – 7.8	DAB 10
Pyrogenicity	< 36.25 EU/ml	DAB 10
Sterility	Sterile	DAB 10

Table. 1 For the Component Specifications for 3.5% Atelocollagen, the assessment of safety is based on the incidence of serious unanticipated adverse events and on a statistical analysis of data on all adverse subject outcomes, including those that are less than serious, anticipated, and not immediately attributed to device implantation. No serious unanticipated adverse device effects were experienced in the study, either for Collagen or the Controls [26].

Results

The evaluation of pharmacokinetics and toxicity is crucial for designing new therapeutic candidates in silico virtual screens, and generative AI outputs a vast number of molecules that must be filtered into a tractable number for synthesis and experimental validation. For this study, the ADMET AI program was used to determine the toxicity of Collage. ADMET is an effective primary filter that evaluates candidate compounds based on their Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) properties. ADMET-AI is a

simple, fast, and accurate digital computer web interface for predicting the ADMET properties of molecules using machine learning models.

The virtual calculation of the blood-brain barrier is shown in Fig 1. [23], which effectively protects brain tissue from circulating

pathogens and other potentially toxic substances, shows the toxicity of Collagen to be low. Collagen itself was shown to be safe and non-toxic.

4.2 Using Quantum Computations to Determine the Drug Toxicity of Collagen

Binding energies between collagen and other molecules [e.g., minerals, drugs, or other proteins] are important for understanding its biological interactions and structural integrity. Binding energies can vary widely depending on the

interaction but often fall in the range of -5 to -15 kcal/mol for collagen-mineral or collagen-drug interactions, indicating moderate to strong binding affinity.

Ground-State Energy (fragment): -200 to -500 kcal/mol (approximate, based on peptide fragments). The HOMO-LUMO

Gap: 5-8 eV, suggesting stability, binding Energy with other Molecules: -5 to -15 kcal/mol for moderate interactions, and Excited-State Energies: 4-5 eV for UV absorption suggests that Collagen is not toxic.

Item	Specification
Cd	< 0.1 ppm
Hg	< 0.1 ppm
Pb	< 0.2 ppm

Table 2. PMMA Heavy Metals Specifications lists the daily requirement of chromium, is 20- 50 µg and a daily intake of 50-200 µg with our food is suggested [1]. The plasma levels range from 0.05 to 0.50 µg Cr/L [4]. The whole blood chromium concentrations were in the range of 20.0 -30.0 µg/L [2], which is about ten times higher than the chromium content in one syringe Artecoll [26].

4.3 Using Laboratory Methods to Determine Drug Toxicity of Collagen

From the Artes laboratory report [23], the toxic metal content in an Artecoll syringe was measured [Table 1]: Pb 0.03 µg, Cr 0.14, Cd 0.017 µg, and Hg < 0.006 µg per 0.5 g Artecoll. The lead content is 0.057 ppm, the chromium content 0.259 ppm, the cadmium content 0.030 ppm, and the mercury content are 0.010 ppm. This means that not only the content of any of these metals is far below 1 ppm, but also the total amount of all heavy metals. This total amount of < 0.4 ppm heavy metals in Artecoll makes any fear of releasing toxic quantities of metals negligible [Artes Medical USA, Inc., 2002]. The current PEL for chromium is 1 mg/m³ TWA. The LD50 of chromium trioxide subcutaneously injected into a dog is 330 mg/kg body weight [1]. About 1 g of potassium dichromate is considered a lethal dose preceded by gastrointestinal bleeding and massive fluid loss [2]. The revised IDLH for chromium is 250 mg Cr/m³ air [23]

The results of the toxicological laboratory data show no evidence that acute exposure to a high chromium concentration would cause irreversible health effects within 30 minutes Table 2 [26].

The duration of a collagen toxicity test can vary depending on the type and scope of the study:

Acute Toxicity Tests: These are short-term studies, typically lasting a few days to a couple of weeks [36].

Sub-chronic Toxicity Tests: These studies usually span around 90 days [36,37].

Chronic Toxicity Tests: These long-term studies can last several months to a year or more [36]

5. Challenges with uses of AI

5.1 Data Privacy

The use of AI and AI algorithms comes with concern of privacy and security of user data. Risk of Data poisoning and alterations underlying models puts a risk to AI users. Implementing Federated learning allows for the training of AI models on decentralized data sources without sharing sensitive data. The fully homomorphic encryption technique used in most federated searching techniques. This is crucial in drug discovery, where patient data and proprietary research information must remain confidential. Federated learning allows collaborative learning across different research institutions or pharmaceutical companies, allowing them to leverage each other's data without compromising privacy. Since raw data is not centralized, the risk of data breaches is minimized,

making it a secure choice for handling sensitive information in drug discovery. Federated Learning can be integrated with AI and quantum computing techniques discussed in the paper, enhancing the predictive capabilities while maintaining data integrity and privacy.

5.2 Ethical Considerations

Despite the promising advancements, several challenges remain in the integration of AI and quantum computing in drug discovery. The ethical implications of using AI in drug discovery must be addressed. Ensuring transparency in AI algorithms and maintaining accountability in decision-making processes are critical to gaining public trust and regulatory approval which can be achieved by using an explainable AI approach. Furthermore, the potential for bias in AI models necessitates ongoing scrutiny to ensure equitable access to new therapies.

5.3 Future Directions

The convergence of AI and quantum computing holds great potential for revolutionizing drug discovery and approval processes. Continued research is needed to refine quantum algorithms and integrate them with AI systems effectively.

6. Discussion

Computational models can lower the costs of bringing new drugs to market by reducing the need for extensive animal studies or large human trials. Quantum Computing, AI (AI), and machine learning (ML) improve in accuracy and generalizability, and there is growing potential for their application in areas traditionally requiring lab data [e.g., toxicology, pharmacodynamics]. Advances in quantum computing, molecular dynamics, and systems biology would help computational models closely mimic biological systems and make predictions more reliable.

AI and Quantum facilitate the drug discovery process by facilitating.

Data Analysis and Pattern Recognition: AI algorithms can analyze vast data sets, including genetic Proteomics and clinical data to identify potential therapeutic targets and predict drug interactions. This capability allows researchers to uncover disease-associated targets and molecular pathways more efficiently than traditional methods, which often rely on trial and error [38,39,40].

Molecular Simulation: Quantum computing enables more accurate simulations of molecular interactions than classical computers. This allows researchers to explore a broader range of potential drug candidates and significantly predict their efficacy and safety, speeding up the drug discovery process [40].

Integration of Computational Models: The combination of AI and quantum computing allows for the development of sophisticated computational models to simulate complex biological systems. This

integration can lead to better-informed decisions in drug development and regulatory processes. Ultimately enhancing patient safety [38].

Reduction of Laboratory Testing: By utilizing computational data the need for extensive laboratory and animal testing can be decreased. This not only reduces cost, but also shortens the time required to bring new drugs to market [40].

Quantifying development costs: The costs are quantified by evaluating the total expenses incurred during the drug development process, including research and development clinical trials and regulatory approvals. Traditional methods can take up to 15 years and cost around \$1 billion while quantum computing can potentially reduce this timeline and cost significantly [40].

Reviewing case studies, researchers may also review case studies where in quantum computing has been implemented in drug discovery to assess the financial and temporal savings achieved compared to conventional methods [40].

6.1 Validation and Accuracy

Computational models must be rigorously validated against experimental data to ensure their predictions are reliable. This includes demonstrating that computational methods are accurate and can reliably substitute for laboratory-generated data. Multiple stakeholders (e.g., academia, industry, and regulatory bodies) would need to validate and reproduce computational data for different types of products.

The burgeoning field of computational data, propelled by AI and Quantum Computing advancements, stands to revolutionize new drug discovery and approval processes. Computational methods can significantly accelerate the identification of potential drug candidates, predict their efficacy, and assess safety, thereby reducing the traditional time and cost burdens associated with pharmaceutical development. By integrating AI and Quantum Computing with extensive chemical databases, researchers can efficiently simulate biological interactions, streamline virtual screening, and predict drug toxicity—ultimately enhancing the likelihood of successful drug development. Furthermore, the implications for the FDA regulatory framework are examined, highlighting how computational data can inform and expedite the approval process, leading to faster review cycles and improved post-market surveillance. The findings advocate for a paradigm shift from traditional laboratory methods to data-driven approaches, emphasizing the need for rigorous validation and collaboration among stakeholders to establish robust regulatory standards for computational models in drug discovery.

6.2 Cost and Time of Computational Versus Laboratory Data

AI is far cheaper per compound than lab-based testing, especially for initial screenings. For example, screening one thousand compounds via AI might cost 10,000 to 50,000, depending on the computational setup [27]. The same screening using vitro methods could cost \$1.00 to ten million and 50 to 500 million using vivo methods once AR AI models are significant. Once developed and validated, models significantly reduce long-term expenses, making them more cost-effective than laboratory methods for large-scale or preliminary screenings.

As the results of this study would suggest, AI is often used as a first-pass filter to predict drug toxicity, reducing the number of compounds that need to be tested in the lab. By prioritizing only those promising candidates for laboratory testing, researchers can combine the speed and cost-effectiveness of AI with the rigor and accuracy of laboratory results, achieving a balance of cost and reliability.

This study suggests that knowing the molecular structure of a drug is a critical factor in determining the toxicity and other aspects of the drug discovery and approval process. Using computational data in drug discovery has transformed the pharmaceutical and biotechnology industries by accelerating research, reducing costs and timeliness, and improving the likelihood of success.

7. Limitations

AI models rely on large, high-quality data sets, but pharmaceutical data is often limited, biased, or proprietary, affecting the model's performance. Also AI generated predictions can lack transparency, making it difficult to understand how a model arrived at a particular conclusion which is critical in drug development in addition AI predictions and consistently accurate, leading to potential failures and identifying effective drug or missing promising candidates AI driven drug discovery must meet stringent FDA regulatory requirements and ethical concerns such as bias in drug development and patient safety to be addressed AI models often struggle with the complexity of biological systems, such as multi target interactions, immune response, and genetic variations despite these challenges, AI will continue to improve and is expected to play a significant role in the future of drug discovery. The findings were intended to demonstrate that the computational assessment of drug toxicity closely aligns with actual laboratory data. This approach not only replicates laboratory results but does so at a significantly reduced cost.

8. Future Work

Due to constraints related to insufficient data and limited time, we were unable to conduct extensive laboratory research. Instead, we focused on a comprehensive literature review, which formed the basis of our review paper. In our future work, we aim to investigate the following questions and hypothesis.

Research Questions:

1. Can AI reliably predict drug toxicity compared to traditional laboratory results?
2. Does the integration of quantum computing enhance the accuracy of molecular modeling and drug discovery?
3. How do AI driven toxicity predictions, compared to laboratory outcomes in terms of cost and time efficiency?

Hypotheses

- H1. AI models can predict the toxicity of drug candidates with a level of accuracy comparable to that of laboratory tests.
- H2. The incorporation of quantum computing into molecular modeling improves the predictive capabilities of AI leading to more accurate toxicity assessments.
- H3. Utilizing AI and QC for toxicity prediction significantly reduces the need for laboratory experiments thereby decreasing both costs and development time in the drug discovery process.

9. Conclusion

AI and Quantum computing offer unique capabilities to tackle complex problems in drug discovery, which is a critical challenge in pharmaceutical research. Regulatory agents will need to adapt to these new technologies. Regulatory processes may become more streamlined, utilizing adaptive clinical trials, accelerating pathways, and better integrating digital data to reduce the time and cost of bringing new drugs to market. Computational data methods could reduce the cost and time involved in experimental drug discovery, allowing researchers to simulate biological interactions and screen large compound libraries more efficiently. Creating virtual data for drug discovery involves several stages, each utilizing specific methods such as simulations, synthetic data generation, data augmentation, and tools to generate, collect, and affect human interaction to identify and develop new drugs. This study suggests that knowing the molecular structure of a drug is a critical factor in determining the toxicity and other aspects of the drug discovery and approval process. Using computational data in drug discovery has transformed the pharmaceutical and biotechnology industries by accelerating research, reducing costs and timeliness, and improving the likelihood of success. In conclusion, the integration of AI and quantum computing represents a transformative shift in drug discovery, offering the potential for faster, more efficient, and more effective therapeutic development. As these technologies continue to evolve, they will likely play a pivotal role in shaping the future of pharmaceuticals.

Acknowledgments

The paper satisfies a partial filament for a Ph.D. in Quantum Computing at Capitol Technology University.

Conflicts of Interest

None declared.

References

- [1] ElZarrad, M. K., Lee, A. Y., Purcell, R., & Steele, S. J. [2022]. Advancing an agile regulatory ecosystem to respond to the rapid development of innovative technologies. *Clinical and Translational Science*, 15[6], 1332-1339. <https://doi.org/10.1111/cts.13267>
- [2] Tao & Qi Q. Make more digital twins. *Nature*. 2019;573:490–1.
- [3] Gelernter, D. *Mirror Worlds: Or: The Day Software Puts the Universe in a Shoebox. How it Will Happen and What it Will Mean*; Oxford University Press: Oxford, UK, 1993.
- [4] Izmailova, E.S., Demanuele, C., and McCarthy, M. [2023]. Digital health technology-derived measures. Biomarkers or clinical outcome assessments? *Clinical and Translational Science*, 16[7], 1113-1120. <https://doi.org/10.1111/cts.1352>
- [5] Asiri, Y. Computing Drug – Drug Similarity from Patient-Centric Data. *Bioengineering* [Basel]. 2023 Feb1;10[2]:182. Doi: 10.3390/bioengineering10020182. PMID: 36829676; PMCID: PMC9952733.
- [6] Vora LK, Gholap AD, Jetha K, Thakur RRS, Solanki HK, Chavda VP. Artificial Intelligence in Pharmaceutical Technology and Drug Delivery Design. *Pharmaceutics*. 2023 Jul 10;15[7]:1916. Doi:
- [7] Ang D, Rakovski C, Atamian HS. De Novo Drug Design Using Transformer-Based Machine Translation and Reinforcement Learning of an Adaptive Monte Carlo Tree Search. *Pharmaceutics* [Basel]. 2024 Jan 27;17[2]:161. Doi: 10.3390/ph17020161. PMID: 38399376; PMCID: PMC10892138.
- [8] Han R, Yoon H, Kim G, Lee H, Lee Y. [2023]. Revolutionizing Medicinal Chemistry: The Application of Artificial Intelligence [AI] in Early Drug Discovery.
- [9] Lee, L. 2023 How AI is accelerating and transforming drug discovery. www.nature.com/biopharmdeal. June 2023
- [10] Sadvbekov, A. A., Sadvbekov, A. V., Liu, Y., Iliopoulos-Tsoutsouvas, C., Huang, X., Pickett, J., Houser, B., Patel, N., Tran, N. K., Tong, F., Zvonok, N., Jain, M. K., Savvch, O., Radchenko, D. S., Nikas, S. P., Petasis, N. A., Moroz, Y. S., Roth, B. L., Makrivannis, A., & Katritch, V. [2022]. Synthon-based ligand discovery in virtual libraries of over 11 billion compounds. *Nature*, 601[7893], 452-2,459A-459S. <https://doi.org/10.1038/s41586-021-04220->
- [11] Wang, Y. & Krstić, P.S. [2023]. Multistate transition dynamics by strong time-dependent perturbation in NISQ era. *Journal of Physics Communications*, 7[7], 075004. <https://doi.org/10.1088/2399-6528/ace67a>
- [12] Cao, Y., Romero, J., & Aspuru-Guzik, A. [2018]. Potential of quantum computing for drug discovery. *IBM Journal of Research and Development*, 62[6], 6-1.
- [13] Vedral, V. [2023]. The Everything-Is-a-Quantum-Wave Interpretation of Quantum Physics. *Quantum Reports*, 5[2], 475. <https://doi.org/10.3390/quantum5020031>
- [14] Hassan, A., & Ibrahim, A. [2023]. The Coming Quantum Computing Evolution in the Pharmaceutical Industry and Drug R&D. *ResearchBerg Review of Science and Technology*, 3[11], 1-16.
- [15] U.S. Food & Drug Administration. [2023]. *Artificial Intelligence in Drug Manufacturing*. Retrieved from https://www.google.com/url?sa=t&source=web&rct=j&opi=89978449&url=https://www.fda.gov/media/165743/download&vedq=2ahUKEwjhe-6-P-IAxW_GDQIHSpNAKsQFnoECBcQAQ&usq=AOvVaw0qw5m2HuZ6Xl7znNB4wd0S
- [16] Pognan F, Beilmann M, Boonen HCM, Czich A, Dear G, Hewitt P, Mow T, Oinonen T, Roth A, Steger-Hartmann T, Valentin JP, Van Goethem F, Weaver RJ, Newham P. The evolving role of investigative toxicology in the pharmaceutical industry. *Nat Rev Drug Discov*. 2023 Apr;22[4]:317-335. doi: 10.1038/s41573-022-00633-x. Epub 2023 Feb 13. PMID: 36781957; PMCID: PMC9924869.
- [17] Wang, Y. & Krstić, P.S. [2023]. Multistate transition dynamics by strong time-dependent perturbation in NISQ era. *Journal of Physics Communications*, 7[7], 075004. <https://doi.org/10.1088/2399-6528/ace67a>
- [18] Huang, B., & von Lilienfeld, O. A. [2020]. Quantum machine learning using atom-in-molecule-based fragments selected on the fly. *Nature Chemistry*, 12[10], 945-951. <https://doi.org/10.1038/s41557-020-0527-z>
- [19] Qiu X, Li H, Ver Steeg G, Godzik A. Advances in AI for Protein Structure Prediction: Implications for Cancer Drug Discovery and Development. *Biomolecules*. 2024 Mar 12;14[3]:339. doi: 10.3390/biom14030339. PMID: 38540759; PMCID: PMC10968151.
- [20] https://pubchem.ncbi.nlm.nih.gov/compound/Collagen-I_-alpha-chain-_98-110
- [21] Protein Data Bank. [2024]. *Crystal structure of Type IV collagen NC1 domain from bovine lens capsule*. <https://www.rcsb.org/structure/1T60>.
- [22] *Computed by OEChem 2.3.0 [PubChem release 2021.10.14]*
- [23] Artes Medical USA, Inc., Report of Laboratory Result of Collagen Toxicity, 2002.

- [24] Computed by PubChem 2.2 [PubChem release 2021.10.4 PubChem [2024]. *Compound Summary of Collagen*. PubChem release 2021.10.14. https://pubchem.ncbi.nlm.nih.gov/compound/Collagen-I_-alpha-chain-_98-110
- [25] Chow, J. C. [2024]. Quantum Computing in Medicine. *Medical Sciences*, 12[4], 67.
- [26] Exploring the future of biopharmaceutical drug discovery: can advanced AI platforms overcome current challenges? [2024]. *Discover Artificial Intelligence*, 4[1], 102. <https://doi.org/10.1007/s44163-024-00188-3>
- [27] Srivastava, R. [2023]. Quantum computing in drug discovery. *Information System and Smart City*, 3[1]
- [28] Cova, T., Vitorino, C., Ferreira, M., Nunes, S., Rondon-Villarreal, P., & Pais, A. [2022]. Artificial intelligence and quantum computing as the next pharma disruptors. *Artificial intelligence in drug design*, 321-347.
- [29] Rayhan, A., & Rayhan, S. [2023]. Quantum Computing and AI: A Quantum Leap in Intelligence.
- [30] Pyrkov, A., Aliper, A., Bezrukov, D., Lin, Y. C., Polykovskiy, D., Kamya, P., ... & Zhavoronkov, A. [2023]. Quantum computing for near-term applications in generative chemistry and drug discovery. *Drug Discovery Today*, 28[8], 103675.
- [31] Kumar, G., Yadav, S., Mukherjee, A., Hassija, V., & Guizani, M. [2024]. Recent Advances in Quantum Computing for Drug Discovery and Development. *IEEE Access*.
- [32] Mishra, R., Mishra, P. S., Mazumder, R., Mazumder, A., & Varshney, S. [2024]. Quantum Computing and Its Promise in Drug Discovery. *Drug Delivery Systems Using Quantum Computing*, 57-92.
- [33] Sharma, P. [2024]. Quantum Computing in Drug Design: Enhancing Precision and Efficiency in Pharmaceutical Development. *Sage Science Review of Applied Machine Learning*, 7[1], 1-9.
- [34] Popa, R., & Dumitrescu, E. [2023]. Drug Discovery in the 21st Century: Exploring the Promises and Potential of Quantum Machine Learning. *Journal of Contemporary Healthcare Analytics*, 7[12], 1-13.
- [35] Chow, James CL. "Quantum Computing in Medicine." *Medical Sciences* 12, no. 4 (2024): 67.
- [36] Marone, P. A., Lau, F. C., Gupta, R. C., Bagchi, M., & Bagchi, D. (2010). Safety and toxicological evaluation of undenatured type II collagen. *Toxicology mechanisms and methods*, 20(4), 175-189.
- [37] <https://echa.europa.eu/registration-dossier/-/registered-dossier/14739/7/6/2>
- [38] <https://petrieflom.law.harvard.edu/2023/03/20/how-artificial-intelligence-is-revolutionizing-drug-discovery/>
- [39] https://quantumzeitgeist.com/quantum-computing-for-drug-discovery-accelerating-research/#google_vignette
- [40] Mak, K. K., & Pichika, M. R. (2019). Artificial intelligence in drug development: present status and future prospects. *Drug discovery today*, 24(3), 773-780.
- [41] Patel, V., & Shah, M. (2022). Artificial intelligence and machine learning in drug discovery and development. *Intelligent Medicine*, 2(3), 134-140.

Supplementary Files

Untitled.

URL: <http://asset.jmir.pub/assets/e3966647796a4a1d90b076da7eff1fdf.docx>

Figures

Untitled.



Untitled.



Untitled.



Related publication(s) - for reviewers eyes onlies

Response to reviewer's comments.

URL: <http://asset.jmir.pub/assets/5afedbe453bbc2c50961a300cfdbee14.pdf>



TOC/Feature image for homepages

Computational Methods for Quantum Computer of Drug Toxicity.

